Back to Results

Transcode Therapeutics Inc (RNAZ)

TransCode Therapeutics Inc. is a NASDAQ-listed common stock company in the healthcare sector that focuses on biopharmaceutical development for cancer. The company is working on therapeutics and diagnostics aimed at treating and identifying cancer, with its lead candidate, TTX-MC138, designed to target microRNA-10b, a regulator associated with metastatic cancer cell survival. Its preclinical pipeline includes TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, along with two indication-agnostic programs. Additional programs include TTX-RIGA, which is based on RNA technology and targets innate immune activation in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based platform for editing cancer-causing genes within tumor cells; and TTX-mRNA, an mRNA platform intended to support cancer vaccine development. The company also has a strategic collaboration with The University of Texas M. D. Anderson Cancer Center and was incorporated in 2016. It is headquartered in Boston, Massachusetts.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-RNAZ
$1.38
-21.8% Downside
Overvalued
Not available
Not available
Weak
0.0%
November 13, 2026
29.967 M
188.1 M
0.3%
12.7%
-21.2
48.9%
Valuation • Fair Value

Transcode Therapeutics Inc (NASDAQ-RNAZ) Fair Value by Valuation Model

Review the available estimates for Transcode Therapeutics Inc (NASDAQ-RNAZ), including Comps Fair Value.

Primary Valuation Read

Fair Value

$1.38

Estimated downside of 21.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$1.38

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Transcode Therapeutics Inc (NASDAQ-RNAZ) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Transcode Therapeutics Inc (NASDAQ-RNAZ)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

500 K

Forward revenue estimate.

EBITDA

-25.262 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Transcode Therapeutics Inc (NASDAQ-RNAZ) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Transcode Therapeutics Inc (NASDAQ-RNAZ)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-21.2

Lower score that deserves closer risk review.

FCF / Net Income

48.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Transcode Therapeutics Inc (NASDAQ-RNAZ). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Transcode Therapeutics Inc (NASDAQ-RNAZ)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

52

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Transcode Therapeutics Inc (NASDAQ-RNAZ), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Transcode Therapeutics Inc (NASDAQ-RNAZ) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Transcode Therapeutics Inc (NASDAQ-RNAZ) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Transcode Therapeutics Inc (NASDAQ-RNAZ) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Transcode Therapeutics Inc (NASDAQ-RNAZ) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Transcode Therapeutics Inc (NASDAQ-RNAZ) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Transcode Therapeutics Inc (NASDAQ-RNAZ) Stock FAQ

Data-supported answers about Transcode Therapeutics Inc (NASDAQ-RNAZ), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.38
Estimated downside 21.8%
Valuation Rating
Overvalued
Estimated downside of 21.8%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Transcode Therapeutics Inc (NASDAQ-RNAZ) is $1.38. This implies an estimated downside of 21.8% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 21.8% versus the current market price.

The current financial health read for Transcode Therapeutics Inc (NASDAQ-RNAZ) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Transcode Therapeutics Inc (NASDAQ-RNAZ) is November 13, 2026.

The latest available data indicates no current dividend yield for Transcode Therapeutics Inc (NASDAQ-RNAZ).

The current market capitalization listed for Transcode Therapeutics Inc is 29.967 M.

The current enterprise value listed for Transcode Therapeutics Inc is 188.1 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Transcode Therapeutics Inc is NASDAQ-RNAZ, and the stock is listed on NASDAQ.

Transcode Therapeutics Inc (NASDAQ-RNAZ) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Transcode Therapeutics Inc is 0.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Transcode Therapeutics Inc is 12.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B